首页> 外文OA文献 >ORAL02.01: Safety and Efficacy of Single-Agent Rovalpituzumab Tesirine, a DLL3-Targeted ADC, in Recurrent or Refractory SCLC

【2h】

ORAL02.01: Safety and Efficacy of Single-Agent Rovalpituzumab Tesirine, a DLL3-Targeted ADC, in Recurrent or Refractory SCLC

机译：Oral02.01：单药ROValpituzuzubab胎草，DLL3靶向ADC，复发或难治性SCLC的安全性和有效性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Todd M. Bauer; David Spigel; Neal Ready; Daniel Morgensztern; Bonnie S. Glisson; Lauren A. Byers; Howard Burris; Francisco Robert; Donald K. Strickland; Maria C. Pietanza; Ramaswamy Govindan; Scott J. Dylla; Stanford Peng; Charles Rudin;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. OA05.03 Single-Agent Rovalpituzumab Tesirine, a?Delta-Like Protein 3 (DLL3)-Targeted Antibody-Drug Conjugate (ADC), in Small-Cell Lung Cancer (SCLC) [J] . David Spigel, M Catherine Pietanza, Todd Bauer, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第1期

机译：OA05.03单孕roralpituzubab tesirine，一种Δδ样蛋白3（dll3） - 小细胞肺癌（SCLC）中的抗体 - 药物缀合物（ADC）
2. OA05.03 Single-Agent Rovalpituzumab Tesirine, a?Delta-Like Protein 3 (DLL3)-Targeted Antibody-Drug Conjugate (ADC), in Small-Cell Lung Cancer (SCLC) [J] . David Spigel, M Catherine Pietanza, Todd Bauer, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第1期

机译：OA05.03单孕roralpituzubab tesirine，一种Δδ样蛋白3（dll3） - 小细胞肺癌（SCLC）中的抗体 - 药物缀合物（ADC）
3. Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study [J] . Morgensztern Daniel, Besse Benjamin, Greillier Laurent, Clinical cancer research: an official journal of the American Association for Cancer Research . 2019,第23期

机译：ROPITUZUZIMAB毒素在第三线及其超出DLL3表达，复发/难治小细胞肺癌中的疗效和安全性：II期三一研究的结果
4. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
5. Rovalpituzumab tesirine a DLL3-targeted antibody-drug conjugate in recurrent small-cell lung cancer: a first-in-human first-in-class open-label phase 1 study [O] . Prof. Charles M Rudin, M Catherine Pietanza, Todd M Bauer, -1

机译：Rovalpituzumab tesirine一种针对DLL3的抗体-药物偶联物在复发性小细胞肺癌中的应用：一项人类首次开创性开放标签的1期研究
6. OA05.03 Single-Agent Rovalpituzumab Tesirine, a Delta-Like Protein 3 (DLL3)-Targeted Antibody-Drug Conjugate (ADC), in Small-Cell Lung Cancer (SCLC) [O] . David Spigel, M Catherine Pietanza, Todd Bauer, 2017

机译：OA05.03单孕酮ROValPituzuabab Teesirine，一种类似的蛋白质3（DLL3） - 小细胞肺癌（SCLC）中的抗体 - 药物缀合物（ADC）

ORAL02.01: Safety and Efficacy of Single-Agent Rovalpituzumab Tesirine, a DLL3-Targeted ADC, in Recurrent or Refractory SCLC

著录项

引文网络

相似文献

相关主题

期刊订阅